DeepCure

Our Chief Scientific Officer Luca Rastelli attended the NextGen Therapies in SJIA, Still’s & MAS Conference organized by the SYSTEMIC JIA FOUNDATION in Washington, DC. It was inspiring to participate in this event, dedicated to advancing the understanding and treatment of Systemic Juvenile Idiopathic Arthritis (SJIA). The foundation’s commitment to supporting families and patients with this complex disease is nothing short of remarkable. At DeepCure, we are developing a novel therapy for diseases like #SJIA and Still’s disease. Collaborating with such a passionate community motivates us to keep pushing the boundaries of scientific discovery and therapeutic development. Thank you to the SJIA Foundation for the opportunity to learn from and contribute to this important conversation. Together, we can work toward a brighter future for patients and families affected by SJIA. For more information about the event, visit https://lnkd.in/edspGaRi For more information about DeepCure, visit www.deepcure.com. #SJIAFoundation?#StillsDisease

Thanks to everyone who supported our poster at American College of Rheumatology Convergence 2024. ???? We presented new in vivo data demonstrating our selective BRD4 (BD2) inhibitor DC-9476 is superior to anti-TNFα, anti-IL6 and JAK2 inhibitor (tofacitinib) therapy in the collagen induced arthritis (CIA) mouse model. Read our #ACR2024 press release: https://lnkd.in/ekhAs4Jd

Thanks Bioworld for covering our #ACR2024 presentation this week. The bromodomain and extra terminal domain (BET) family of proteins, including BRD4, regulates the transcription of multiple proinflammatory and immunoregulatory genes. BRD4 is involved in immune-related disorders such as rheumatoid arthritis (RA). https://lnkd.in/e65KcM5m

Our Co-Founder and CTO Thrasyvoulos Karydis spoke at #ChemTalks24 hosted by Chemaxon. Is AI in Drug Discovery trapped in the data of the past? ???? Thras talks about removing biases from the DMTA cycle, and introduces an AI/design framework for identifying novel binding opportunities while taking into account ADME-tox profile and synthesizability. He walks you through how a robotic synthesis system opens up novel chemical spaces with reproducible multi-step synthesis from 100+ reaction types. Watch the presentation here: ???? https://lnkd.in/eShMg4Ee

Breaking Silos in Drug Discovery: How AI and Automation Deliver New Medicines Faster Drug discovery is hampered by the costly, time-consuming manual synthesis process. Previous efforts at automation have struggled to achieve sufficient chemical diversity, and cost-effectiveness. This Digital Dialogue will examine how AI/ML and Automation applications can deliver new medicines to patients with greater speed and efficiency. 16:00 CET – 15:00 GMT – 10:00 EST Thursday 21st?November, 15:00 – 16:00 UK Speakers:? Thrasyvoulos Karydis, Chief Technology Officer and & Co-Founder, DeepCure Christos A. Nicolaou, Sr Director, Digital Chemistry, Novo Nordisk Free registration open: https://lnkd.in/eFwbkMgJ Key discussion points include: ·??????How can drug discovery navigate the complexity of balancing multiple, often conflicting, pharmaceutical objectives to develop effective treatments?? Learn how to apply a more holistic approach to the Design, Make,?Test and Analyze (DMTA) Cycle to deliver time and resource gains in drug discovery. ·??????How can complex AI designs be turned into testable molecules? Learn the opportunities and potential pitfalls of integrating AI molecule design and robotic chemical synthesis for small molecule drug discovery.?? ·??????How can AI decision-making remove bottlenecks in drug discovery? Learn how errors and other issues in automated production can be bottlenecks that require human intervention, and how AI can potentially resolve these issues with real time decision-making. #labofthefuture #drugdiscovery #ai #automation

Kfir Schreiber, co-founder and CEO of DeepCure, discusses the company’s AI technology platform, its focus on autoimmune diseases, and why he believes its technology will allow it to develop small molecule drugs that can provide alternatives to biologics to treat these conditions. https://lnkd.in/dd7wV-Ry

Interested in one of the key bottlenecks in drug discovery? Join Christos A. Nicolaou from Novo Nordisk and Thrasyvoulos Karydis from DeepCure to hear about the future of automation and AI for chemical synthesis. #drugdiscovery #automation #pharmaceuticals #artificialintelligence

Our CEO Kfir Schreiber was on the #BioFuture24 panel: “Real Use of AI in Pharma: Today and in the Near Future,” in New York this week. ???? The panel explored the continuously evolving uses of AI in the pharmaceutical and biotech industries, and the impact it can have thanks to its multiple cutting-edge applications. The conversation discussed powering new drug discovery platforms to accelerating clinical trials and increasing efficiency across the whole drug development process, ultimately improving patient outcomes. Moderator: David Schull, President, Russo Partners Panelists: * Xiaorong He, Senior Vice President, Head, Global Development Sciences & US Site Head of Non-Clinical Development, Boehringer Ingelheim * Nathan McBride, Senior Vice President, IT, Xilio Therapeutics, Inc. * Friso Postma, VP, Artificial Intelligence Drug Discovery, BioXcel Therapeutics, Inc. * Kfir Schreiber, Co-Founder & CEO, DeepCure

Ideagen? speaks with our co-founder and CTO Thrasyvoulos Karydis about the synergetic power of #AI and human expertise in overcoming the traditional constraints of drug design. Thras shares real-life narratives of initial challenges turning into triumphs, illustrating AI's potential to reshape the landscape of drug discovery. He discusses DeepCure's goals, including upcoming clinical trials for DC-9476 targeting rheumatoid #arthritis. As DeepCure continues to push boundaries, find out how it plans to repeatedly design transformative therapeutics and make a lasting impact on patient lives. Don't miss this insightful episode that promises a glimpse into the future of healthcare innovation. #ideagenglobal #globalpartnerships #deepcure Watch here: https://lnkd.in/e8ACYRqu

We’re excited to present our first ex vivo data from rheumatoid arthritis patients at ACR Convergence 2024, held November 14-19, in Washington DC! Details of the presentation: Poster Title: DC-9476, a novel selective BRD4 (BD2) inhibitor targets key inflammatory arthritis pathways and is highly efficacious in the collagen induced arthritis mouse model of rheumatoid arthritis Session: RA – Animal Models Poster Date/Time: November 17, 2024, 10:30 AM – 12:30 PM ET Presenter: Dr. Kulveer Mankia, Clinical Associate Professor and Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital Read the release: ???? https://lnkd.in/ekhAs4Jd